Sun Hwa Kim
Overview
Explore the profile of Sun Hwa Kim including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
182
Citations
2924
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ra J, Kim S
Child Health Nurs Res
. 2025 Feb;
31(1):28-39.
PMID: 39895295
Purpose: This study explored the intrapersonal, interpersonal, and school factors, following the socioecological model, associated with sugar-sweetened beverage (SSB) consumption in Korean high-school students. Methods: A total of 231 students...
2.
Lee Y, Seol Y, Kim B, Choi K, Hong J, Park C, et al.
Front Oncol
. 2025 Jan;
14:1495216.
PMID: 39876900
Purpose: This study aimed to provide quantitative information for implementing Lattice radiotherapy (LRT) using a medical linear accelerator equipped with the Millennium 120 multi-leaf collimator (MLC). The research systematically evaluated...
3.
Park B, Kim E, Jang H, Kim Y, Ryu Y, Choi J, et al.
Theranostics
. 2025 Jan;
15(3):1122-1134.
PMID: 39776792
Acute liver failure (ALF) is characterized by rapid hepatic dysfunction, primarily caused by drug-induced hepatotoxicity. Due to the lack of satisfactory treatment options, ALF remains a fatal clinical disease, representing...
4.
Kim E, Ryu Y, Choi J, Park D, Lee J, Chi S, et al.
Biomater Res
. 2024 Oct;
28:0095.
PMID: 39434899
Acquired resistance to chemotherapy is a major challenge in the treatment of triple-negative breast cancer (TNBC). Despite accumulated evidence showing microRNA-21 (miR-21) as a vital regulator of tumor progression, the...
5.
Jang H, Choi J, Park D, Han G, Kim E, Kim K, et al.
Theranostics
. 2024 Sep;
14(14):5413-5428.
PMID: 39310094
Oral chemotherapy has been emerging as a hopeful therapeutic regimen for the treatment of various cancers because of its high safety and convenience, lower costs, and high patient compliance. Despite...
6.
Lee J, Yoon H, Ko Y, Kim E, Song S, Hue S, et al.
ACS Nano
. 2024 Aug;
18(33):22298-22315.
PMID: 39117621
A series of successes in RNA interference (RNAi) therapies for liver diseases using lipid nanoparticles and -acetylgalactosamine have heralded a current era of RNA therapeutics. However, alternative delivery strategies are...
7.
Kim E, Choi J, Jang H, Kim Y, Lee J, Ryu Y, et al.
Theranostics
. 2024 Jul;
14(10):3777-3792.
PMID: 38994018
Growing evidence has demonstrated that miRNA-21 (miR-21) upregulation is closely associated with tumor pathogenesis. However, the mechanisms by which miR-21 inhibition modulates the immunosuppressive tumor microenvironment (TME) and improves tumor...
8.
Choi J, Park B, Yeon Park J, Shin D, Lee S, Yoon H, et al.
Adv Mater
. 2024 Jun;
36(38):e2405475.
PMID: 38898702
While proteolysis-targeting chimeras (PROTACs) hold great potential for persistently reprogramming the immunosuppressive tumor microenvironment via targeted protein degradation, precisely activating them in tumor tissues and preventing uncontrolled proteolysis at off-target...
9.
Park B, Han G, Jin D, Gil K, Shin D, Lee J, et al.
ACS Nano
. 2024 Jun;
18(25):16297-16311.
PMID: 38867457
While mesalamine, a 5-aminosalicylic acid (5-ASA), is pivotal in the management of inflammatory bowel disease (IBD) through both step-up and top-down approaches in clinical settings, its widespread utilization is limited...
10.
Kim Y, Choi J, Kim E, Park W, Jang H, Jang Y, et al.
Adv Sci (Weinh)
. 2024 Mar;
11(22):e2309917.
PMID: 38520717
Lipid nanoparticles (LNPs) exhibit remarkable mRNA delivery efficiency, yet their majority accumulate in the liver or spleen after injection. Tissue-specific mRNA delivery can be achieved through modulating LNP properties, such...